1-2 of 2
Hanno Ulmer, PhD
Close
Sort by
Journal Articles

CELSG CML 11 “ISTAHIT” Phase III Study – Planned Interim Analysis: High Doses of Imatinib Mesylate (800mg/day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph + /BCR-ABL + CML Patients in Chronic Phase.

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominic Fong, MD, Thomas Lion, MD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Stefan Goranov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Radka Oucheva, MD, Hanno Ulmer, PhD, Marthin Kwakkelstein, MD, Gianluca Fincato, MD, Guenther Gastl, MD
Journal: Blood
Blood (2008) 112 (11): 1112.
https://doi.org/10.1182/blood.V112.11.1112.1112
Published: 2008
Journal Articles

Multicenter, Randomized, Phase III Study Comparing Imatinib (Glivec) Standard Dose (400 mg/d) with Imatinib High Dose Induction (800 mg/d) Followed by Imatinib Maintenance (400 mg/d) in Patients with Pretreated Ph + /BCR-ABL + CML in Chronic Phase - Results from the First Planned Interim Analysis (CELSG-CML 11 ISTAHIT Study).

Andreas L. Petzer, MD, Dominik Wolf, MD, Dominik Fong, MD, Thomas Lion, MD, PhD, Irina Dyagil, MD, Zvenyslava Masliak, MD, Darinka Boskovic, MD, Laimonas Griskevicius, MD, Sandra Lejniece, MD, Emil Spasov, MD, Liana Gercheva, MD, Aleksandar Stojanovic, MD, Dontcho Peytchev, MD, Nikolay Tzvetkov, MD, Rasa Griniute, MD, Atanas Stanchev, MD, Martin Kwakkelstein, MD, Hanno Ulmer, PhD, Guenther A. Gastl, MD
Journal: Blood
Blood (2007) 110 (11): 1048.
https://doi.org/10.1182/blood.V110.11.1048.1048
Published: 2007